Skip to main content
Triangle logo TriangleGet started

Azacitidine (NCT05554406)

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial): a one-minute explainerNCT055544061 min

Azacitidine trial for Acute Myeloid Leukemia (NCT05554406). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults aged 18–59 with newly diagnosed, untreated, adverse-risk acute myeloid leukemia assigned through myeloMATCH. FLT3 mutations, t(9;22), and acute promyelocytic leukemia are excluded.

The idea: compare cytarabine/daunorubicin, standard or liposomal, with or without venetoclax, and azacitidine plus venetoclax. These are five separate regimens. Venetoclax blocks BCL-2, a protein that supports leukemia-cell survival. Researchers compare remission without measurable residual disease.

This phase 2 study plans 335 patients. Paul Shami leads through SWOG; 203 US locations list recruitment.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.